1. van Vugt MA. Shutting down the power supply for DNA repair in cancer cells. Journal of Cell Biology. 2017 Feb;216(2):295-297.
  2. Ruf S, Heberle AM, Langelaar-Makkinje M, Gelino S, Wilkinson D, Gerbeth C, Schwarz JJ, Holzwarth B, Warscheid B, Meisinger C, van Vugt MA, Baumeister R, Hansen M, Thedieck K. PLK1 (polo like kinase 1) inhibits MTOR complex 1 and promotes autophagy. Autophagy. 2017 Jan 19:0. [Epub ahead of print]
  3. Fedoseienko A, Wieringa HW, Wisman GB, Duiker E, Reyners AK, Hofker MH, van der Zee AG, van de Sluis B, van Vugt MA. Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer. PLoS One. 2016 Oct 27;11(10):e0165385.
  4. Bense RD, Sotiriou C, Piccart-Gebhart MJ, Haanen JB, van Vugt MA, de Vries EG, Schröder CP, Fehrmann RS. Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer. Journal of the National Cancer Institute. 2016 Oct 13;109(1).
  5. de Boer HR, Guerreo Llobet, van Vugt MA. Controlling the response to DNA damage by the APC/C-Cdh1. Cellular and Molecular Life Sciences. 2016 Mar;73(5):949-60.
  6. Alkema NG, Wisman, GB, van der Zee AG, van Vugt MA, de Jong S. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: different models for different questions. Drug Resistance Updates. 2016 Jan;24:55-69.
  7. Wieringa HW, van der Zee, AGJ, de Vries, EG, van Vugt MABreaking the DNA damage response in cervical cancer for treatment optimization. Cancer Treatment Reviews. 2016 Jan;42:30-40.
  8. Dickreuter E, Eke I, Krause M, Borgmann K, van Vugt MA, Cordes N. Targeting of β1 integrins impairs DNA repair for radiosensitization of head and neck cancer cells. Oncogene, 2016 Mar 17;35(11):1353-62.
  9. Heijink AM, Blomen VS, Degener, F, Matsushita, FY, Bisteau, XKaldis P, Foijer F, van Vugt MA. A Haploid genetics screen identifies the G1/S transition as a determinant of Wee1 inhibitor sensitivity. Proc. Natl. Acad. Sci. U.S.A, 2015 Dec 8;112(49):15160-5
  10. Hengeveld RC, de Boer HR, Schoonen PM, de Vries EG, Lens SM, van Vugt MARif1 is required for resolution of ultrafine DNA bridges in anaphase to ensure genomic instability. Developmental Cell, 2015 Aug 24;34(4):466-74.
  11. Krajewska M, Fehrmann RS, de Vries EG, van Vugt MA. Regulators of homologous recombination repair as novel targets for cancer treatment. Frontiers in Genetics,  2015 Mar 20;6:96.
  12. Alves IT, van Vugt MAPlk1 Manages DNA break repair during mitosis. Cell Cycle. 2015 May 3;14(9):1356-7.
  13. Fehrmann RS, Karjalainen JM, Krajewska M, Westra HJ, Maloney D, Simeonov A, Pers TH, Hirschhorn JN, Jansen RC, Schultes EA, van Haagen HH, de Vries EG, te Meerman GJ, Wijmenga C, van Vugt MA, Franke L. Gene expression analysis identifies global gene dosage sensitivity in cancer. Nature Genetics. 2015 Feb;47(2):115-25.
  14. Tamas, K., Domanska, U.M., van Dijk, T.H., Timmer-Bosscha, H., Havenga, K., Karrenbeld, A., Sluiter, W.J., Beukema, J.C., van Vugt, M.A., de Vries, E.G., Hospers, G.A., Walenkamp, A.M. CXCR4 and CXCL12 Expression in Rectal Tumors of Stage IV Patients Before and After Local Radiotherapy and Systemic Neoadjuvant Treatment. Current Pharmaceutical Design, 2015;21(17):2276-83.
  15. Lafranchi, L., de Boer, H.R., de Vries, E.G., Ong, S.E., Sartori, A.A., van Vugt, M.A. APC/CCdh1 controls CtIP stability during the cell cycle and in response to DNA damage. EMBO J. 2014 Dec 1;33(23):2860-79
  16. Krajewska, M., Fehrmann, R.S., Schoonen, P.M., Labib, S., de Vries, E.G., Franke, L., van Vugt, M.A. ATR inhibition preferentially targets homologous recombination-deficient tumor cells. Oncogene. 2014 Sep 1
  17. Alkema, N.G., Tomar, T., van der Zee, A.G., Everts, M., Meersma, G.J., Hollema, H., de Jong, S., van Vugt, M.A., Wisman, G.B. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer. Gynecological Oncology. 2014 Mar 20.
  18. Domanska, U.M., Boer, J.C., Timmer-Bosscha, H., van Vugt, M.A., Hoving, H.D., Kliphuis, N.M., Rosati, S., van der Poel, H.G., de Jong, I.J., de Vries, E.G., Walenkamp, A.M. CXCR4 inhibition enhances radiosensitivity, while inducing cancer cell mobilization in a prostate cancer mouse model. Clin Exp Metastasis. 2014 Oct;31(7):829-39.
  19. Koster, R., van Vugt, M.A., Timmer-Bosscha, H., Gietema, J.A., de Jong, S. Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer. Expert Rev Mol Med. 2013 Sep 30;15:e12.
  20. A.M. Heijink, A.M., Krajewska, M., van Vugt, M.A. The DNA damage response during mitosis. Mutation research, 2013 Jul 21
  21. Huisman, C., Wisman, G.B., Kazemier, H.G., van Vugt, M.A., van der Zee, A.G., Schuuring, E., Rots, M.G. Functional validation of putative tumor suppressor gene C13ORF18 in cervical cancer by Artificial Transcription Factors. Molecular Oncology, 2013 Jun;7(3):669-79
  22. Krajewska, M., Heijink, A.M., Bisselink, Y.J., Seinstra W.I., Sillje, H.H., de Vries, E.G., van Vugt, M.A. Forced activation of Cdk1 via Wee1 inhibition impairs homologous recombination. Oncogene, 2012, epub ahead of print
  23. Bensch, F., van Kruchten, M., Lamberts, L.E., Schröder, C.S., Hospers, G.A.P., Brouwers, A.H., van Vugt, M.A., de Vries, E.G. Molecular imaging for monitoring treatment response in breast cancer patients. European Journal of Pharmacology, 2013, in press
  24. Reyners, A.K., de Munck, L., Erdkamp, F.L., Smit, W.M., Hoekman, K., Lalisang, R.I., de Graaf, H., Wymenga, A.N., Polee, M., Hollema, H., van Vugt, M.A., Schaapveld, M., Willemse, P.H; for the DoCaCel Study Group. A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study. Annals of Oncology, 2012, epub ahead of print
  25. Roossink, F., Wieringa, H.W., Noordhuis, M.G., Ten Hoor, K.A., Kok, M., Slagter-Menkema, L., Hollema, H., de Bock, G.H., Pras, E., de Vries, E.G., de Jong, S., van der Zee, A.G., Schuuring, E., Wisman, G.B., van Vugt, M.A. The role of ATM and 53BP1 as predictive markers in cervical cancer. International Journal of Cancer, 2012, epub ahead of print
  26. de Vries, E.G., Oude Munnink, T.H., van Vugt, M.A., and Nagengast, W.B. Toward Molecular Imaging-Driven Drug Development in Oncology. Cancer Discovery, 2011, 1(1): 25-8
  27. Kooter, I.M., van Vugt, M.A., Jedynska, A.D., Tromp, P.C., Houtzager, M.M., Verbeek, R.P., Kadijk, G., Mulderij, M., Krul, C.A. Toxicological characterization of diesel engine emissions using biodiesel and a closed soot filter. Atmospheric Environment, 2011, 45,(8), 1574-1580
  28. Heijink, D.M., de Vries, E.G., Koornstra, J.J., Hospers, G.A., Hofstra, R.M., van Vugt, M.A., de Jong, S., Kleibeuker, J.H. Perspectives for tailored chemoprevention and treatment of colorectal cancer in Lynch syndrome. Critical Reviews in Oncology and Hematology, 2011, 80(2):264-77.
  29. Krajewska, M., van Vugt, M.A. Building a great wall around mitosis: evolutionary conserved roles for the Greatwall/MASTL kinases in securing chromosome stability. Cell Cycle,2010, 9(19):3842.
  30. Reinhardt, H.C., Hasskamp, P., Schmedding, I., Morandell, S., van Vugt, M.A., Wang, X., Linding, R., Ong, S.E., Weaver, D., Carr, S.A., Yaffe, M.B. DNA damage activates a spatially distinct late cytoplasmic cell-cycle checkpoint network controlled by MK2-mediated RNA stabilization. Molecular Cell, 2010, 40(1):34-49.
  31. van Harn, T., Foijer, F., van Vugt, M., Banerjee, R., Yang, F., Oostra, A., Joenje, H., te Riele, H. Loss of Rb proteins causes genomic instability in the absence of mitogenic signaling. Genes and Development, 2010, 24(13):1377-88.
  32. van Vugt, M.A., Yaffe, M.B. Cell cycle re-entry mechanisms after DNA damage checkpoints: giving it some gas to shut off the breaks! Cell Cycle, 2010, 9(11):2097-101.
  33. van Vugt, M.A., Gardino, A.K., Linding, R., Ostheimer, G., Reinhardt H.C., Tan, C., Maio, H., Keezer, S., Li, R., Pawson, T., Lewis, T., Brummelkamp, T.R., Yaffe, M.B. A mitotic phosphorylationfeedback network connects Cdk1, Plk1, 53BP1 and Chk2 to inactivate the G2/M DNA damage checkpoint. PLoS Biology, 2010, 8, e1000287
  34. Leuken, R., Clijsters, L., van Zon, W, Lim, D., Yao, X., Wolthuis, R.M., Yaffe, M.B, Medema, R.H, Van Vugt, M.A. Polo-like kinase-1 controls activation of the APC/C-Cdh1 through hCdc14A. PLoS One, 2009, 4:e5282
  35. Kishi, K., van Vugt M.A., Okamoto K., Hayashi, Y., Yaffe, M.B. Functional dynamics of Polo-like kinase 1 at the centrosome. Molecular and Cellular Biology, 2009, 29:3134-50.
  36. Linding, R*., Jensen L.L.,* Ostheimer G*., van Vugt, M.A., Jørgensen, C., Miron, I.M., Diella., F., Colwill, K., Taylor, L., Elder, K., Metalnikov, P., Nguyen, V., Pasculescu, A., Jin, J., Park, J.G., Samson, L., Woodgett J.R., Russell, R.B., Bork, P., Yaffe, M.B.*, Pawson, T*. Systematic discovery of in vivo phosphorylation networks. Cell, 2007, 129(7):1415-26 (* equal contribution)
  37. Wilker. E., van Vugt, M.A. Artim S.A., Huang, P.H., Petersen C.P., Reinhardt H.C., Feng Y., Sharp, P.A., Sonenberg, N., White, F.M., Yaffe, M.B., 14-3-3sigma controls mitotic translation to facilitate cytokinesis. Nature, 2007, 446:329-32.
  38. Freire, R, van Vugt, M.A., Mamely, I., Medema, R.H. Claspin: timing the cell cycle arrest when the genome is damaged. Cell Cycle, 2006, 5:2831-4
  39. van Vugt, M.A.,* Mamely, I.* Smits, V.A., Semple, J.I., Lemmens, B. Perrakis, A., Medema, R.H., Freire, R., Polo-like kinase-1 controls proteasome-dependent degradation of Claspin during checkpoint recovery. Current Biology, 2006, 16:1950-5. (* equal contribution)
  40. Tanenbaum, M.E., Galjart, N., van Vugt, M.A*. Medema, R.H*. CLIP-170 facilitates the formation of kinetochore-microtubule attachments. EMBO Journal, 2006, 25:45-57
  41. van Vugt, M.A., Bras, A Medema, R. H., Restarting the cell cycle when the checkpoint comes to a halt. Cancer Research, 2006, 65:7037-40
  42. van Vugt, M.A., Medema, R. H., Getting in and out of mitosis with Polo-like kinase-1. Oncogene, 2005, 24:2844-59
  43. van Vugt, M.A., R.H. Medema., Polo-like kinase-1: activity measurement and RNAi-mediated knockdown. Methods in Molecular Biology, 2005, 296: 355-369
  44. 23. van de Weerdt B.C, van Vugt, M.A.Lindon, C., Kauw, J.J., Rozendaal, M.J., Klompmaker, R., Wolthuis, R.M. Medema, R.H. Uncoupling anaphase-promoting complex/cyclosome activity from spindle assembly checkpoint control by deregulating polo-like kinase 1. Molecular and Cellular Biology, 2005, 25:2031-44.
  45. van Vugt, M.A., Bras, A Medema R.H., Checkpoint adaptation and recovery: back with Polo after the break. Cell Cycle, 2004, 3:1383-6
  46. van Vugt, M.A.,* Bras, A* Medema, R.H. Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells. Molecular Cell, 2004, 15:799-811. (* equal contribution)
  47. van Vugt, M.A., Van de Weerdt., B.C., Vader, G., Klompmaker, R., Jansen H., Calafat, G., Wolthuis, R.M., Medema, R.H. Polo-like kinase-1 is required for bipolar spindle formation but is dispensable for anaphase promoting complex/Cdc20 activation and initiation of cytokinesis. Journal of Biological Chemistry, 2004, 279:36841-54
  48. van Vugt, M.A., Smit, V.A., Klompmaker, R., Medema, R.H. Inhibition of Polo-like kinase-1 by DNA damage occurs in an ATM- or ATR-dependent fashion. Journal of Biological Chemistry, 2001, 276:41656-60